AMGN
AmgenPrevious close
466.01
Change
+5.28 / +1.15%
P/E (TTM) ?
28.5
Market Cap
$254B
1M
+10.56%
S&P 500 −0.91% over same period
Volume / Avg Volume
3.3M / 2.5M
1.32× average
Latest earnings analysisFY2026 Q2Reported 2026-08-04
Amgen Q2 FY2026: revenue up 10% to $10.05 billion, EPS tops estimates
Amgen beat on profit and lifted its full-year revenue outlook: second-quarter revenue rose 10.0% to $10.05 billion and net income hit $2.38 billion. The bullish read is that six growth drivers now carry the portfolio, offsetting steep declines in older drugs. Read the scorecard below as a test of quality: growth is real, but a chunk of the profit jump comes from lower amortization, not operations.
Read the full analysis →Revenue$10.05BYoY +9.50%
EPS (non-GAAP)$6.29Beatest. $5.73
Next-quarter revenue guidance$38.80B ±1.5%YoY +285.90%
Next-day move+4.57%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-08-04 | $10.1B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-30 | $8.6B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-03 | $36.8B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-11-04 | $9.6B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-08-05 | $9.2B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-01 | $8.1B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 68 of its 5-year rangeMid-range
5-year range 18.1 – 55.3 · Median 25.8
Last 4 quarters: $0 in buybacks + $5.3B in dividends, 2.08% of market cap combined
P/E (TTM)
28.5
P/B
21.3
P/S
6.5
Dividend Yield
3.21%
Earnings Reaction
Over the last 6 reports, the stock moved ±5.2% on average on the first trading day after, rising 3 times
Most recent +4.57%
Volatility & Correlation
1-year beta 0.44 · Correlation with S&P 500 0.19Low beta
Annualized volatility 30% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 4 · $4.1MNet selling $4.1M
- 08-13Khosla RachnaSVP, Business DevelopmentSell$0.52M1,252 shares · Avg price 416.43
- 08-11Khosla RachnaSVP, Business DevelopmentSell$0.83M2,000 shares · Avg price 412.57
- 08-06Grygiel Nancy A.SVP & CCOSell$1.2M2,970 shares · 2 trades · Avg price 402.16
- 08-06Miller DerekSVP, Human ResourcesSell$1.6M3,890 shares · 2 trades · Avg price 402.54
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 10.05 | +9.5% | 72.0% | 2.38 | 4.37 |
| FY2026 Q1 | 8.62 | +5.8% | 68.2% | 1.82 | 3.34 |
| FY2025 Q4 | 9.87 | +8.6% | 69.8% | 1.33 | 2.45 |
| FY2025 Q3 | 9.56 | +12.4% | 67.8% | 3.22 | 5.93 |
| FY2025 Q2 | 9.18 | +9.4% | 67.2% | 1.43 | 2.65 |
| FY2025 Q1 | 8.15 | +9.4% | 63.6% | 1.73 | 3.20 |
| FY2024 Q4 | 9.09 | +10.9% | 65.7% | 0.63 | 1.17 |
| FY2024 Q3 | 8.50 | +23.2% | 61.1% | 2.83 | 5.22 |
| FY2024 Q2 | 8.39 | +20.1% | 61.4% | 0.75 | 1.38 |
| FY2024 Q1 | 7.45 | +22.0% | 57.0% | -0.11 | -0.21 |
| FY2023 Q4 | 8.20 | +19.8% | 62.0% | 0.77 | 1.42 |
| FY2023 Q3 | 6.90 | +3.8% | 73.8% | 1.73 | 3.22 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |
| ABT | 39.1 | +7.8% | 56.2% | +7.46% | Neutral |